Generated Record Revenues with Robust 50% Year-over-Year Revenue Growth in Q4 2023; Generated Positive Quarterly Net Income Providing Full-Year 2024 Revenue Guidance of $37-$40 Million with Continued Profitability Momentum and Cash Generation Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a world leader in advanced and non-invasive treatment for brain disorders, today repo ...

Brainsway (BWAY) is slated to report its fourth-quarter 2023 results on Mar 6 before market open.The company posted a diluted net loss of 1 cent per share in the last reported quarter, which was narrower than the Zacks Consensus Estimate of a loss of 7 cents per share. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on three occasions and matched in one quarter, the average beat being 49.49%.Let's see how things have shaped up prior to this announcement.Factors at PlaySimil ...

BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to ...

From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as biotech, offers exciting disruptive solutions with the potential to expand to market caps worth trillions! With new catalysts such as artificial intelligence and quantum computing offering methods to unlock complicated data sets to hasten drug development pipelines, it’s no wonder that this market has a projected com ...

U.S. stock markets have retreated in January after a sharp rally in 2023. The euphoria surrounding technology stocks evaporated primarily owing to the uncertainty regarding the time when the Fed would initiate the first cut in the benchmark interest rate.Recently, a few key Fed FOMC members said that although they believe that the rate hike regime is over, they are yet to be convinced that the economic condition is conducive enough for an immediate rate cut.Hotter-than-expected nonfarm payrolls and consumer ...

Company Participants Hadar Levy - Chief Executive Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Brainsway Ltd (NASDAQ:BWAY) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Brian Ritchie - Investor Relations, LifeSci Advisors Ido Marom - Chief Financial Officer Jayson Bedford - Raymond James Carl Byrnes - Northland Capital Markets Boobalan Pachaiyappan - H.C. Wainwright Good day and welcome to BrainsWay Third Quarter 2023 Earnings Call. At this time all partic ...

There are no further questions in the queue at this time. I will turn the call back over to Hadar for any closing remarks. Hadar Levy I would like to thank all of the investors, analysts and other participants for their interest in BrainsWay. With that, please enjoy the rest of your day. Thank you. Operator Thank you, ladies and gentlemen. This concludes your teleconference. Please disconnect your lines. Okay. Got it. And then Ido on the financial side, could you just give us a sense, you talked about a red ...

BrainsWay Ltd. (NASDAQ:BWAY) Q1 2023 Earnings Call May 17, 2023 8:30 AM ET Brian Ritchie - Investor Relations, LifeSci Advisors Scott Areglado - Senior Vice President and Chief Financial Officer Jeffery Cohen - Ladenburg Thalmann Boobalan Pachaiyappan - H.C. Wainwright I would now like to turn the conference over to your host, Brian Ritchie with LifeSci Advisors. Thank you. You may begin. The format for today's call will be a discussion of recent trends and business updates from Hadar, followed by a detaile ...

Business, Economic and Industry risks · Clinical trials involve a lengthy and expensive process with an uncertain outcome, which may delay or cause us to abandon the development of Deep TMS for additional indications. · We bare the risk of product liability lawsuits and warranty claims which we might harm our business, exceed our insurance policy coverage and we may not have enough funds to cover such claims or lawsuits damages. · The misuse or off-label use of Deep TMS may harm our reputation in the market ...

Moving to the balance sheet. We ended the fourth quarter with cash, cash equivalents and short-term deposits of $47.9 million, as compared to $57.3 million at December 31, 2021. Based on our robust U.S. pipeline and continued momentum internationally, we are confident in our positive outlook for 2023. To reiterate what Hadar said, we anticipate annual revenue growth over last year and to show improvements in cost containment over 2022. This concludes our prepared remarks. I will now ask the operator to open ...